[S(R)]-N-[(1R)-1-[2-(二苯基膦)苯基]乙基]-2-叔丁基亚磺酰胺
[S(R)]-N-[(S)-[2-(二环己基膦)苯基](5,6,7,8-四氢-5,5,8,8-四甲基-2-萘基)甲基]-2-叔丁基亚磺酰胺
[S(R)]-N-[(S)-[3,5-二叔丁基-4-甲氧基苯基][2-(二环己基膦)苯基]甲基]-2-叔丁基亚磺酰胺
[S(R)]-N-[(1S)-1-[2-(二环己基膦)苯基]乙基]-N-甲基-2-叔丁基亚磺酰胺
[S(R)]-N-[(1S)-1-[2-(9-蒽基)苯基]-2-(二苯基膦)乙基]-N-甲基-2-叔丁基亚磺酰胺
[S(R)]-N-[(S)-[2-(二苯基膦)苯基]苯基甲基]-N-甲基-2-叔丁基亚磺酰胺
溶解性 |
|
存贮条件 | 储存温度-20°C |
产品介绍 | PJ34是PARP-l/2抑制剂,EC50为20 nM。 |
生化机理 | PJ34 inhibited peroxynitrite-induced cell necrosis with EC50 of 20 nM. PJ34 provides cardioprotection by decreasing myocardial infarct size and enhancing postischemic regional and global functional recovery .Treatment with PJ34 increased NIS promoter activity without affecting PARP-1 binding to the promoter sequence, in addition to an increase of histone modification activation marks (H3K9K14ac, H3K4me3) . |
别名 | PJ-34;PJ 34; N-(6-氧代-5,6-二氢菲啶-2-基)-2-(N,N-二甲基氨基)乙酰胺;PJ-34;PJ 34;N-(6-Oxo-5,6-dihydrophenanthridin-2-yl)-2-(N,N-dimethylamino)acetamide |